Literature DB >> 9207409

Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukaemia: correlation with the expression of TGF-beta receptors.

L Lagneaux1, A Delforge, D Bron, M Massy, M Bernier, P Stryckmans.   

Abstract

We investigated the potential role of transforming growth factor-beta (TGF-beta) on spontaneous and cytokine-induced proliferation of B-cell chronic lymphocytic leukaemia (B-CLL) cells in vitro. Purified B lymphocytes from 21 B-CLL patients were cultured for 5 d in the presence of medium alone, IL-2 and/or IL-10, in the presence or absence of TGF-beta, and proliferation was measured by 3H-thymidine incorporation. TGF-beta inhibited B-cell proliferation in the majority of patients (15/21) but no inhibition was detected in 6/21 patients whatever the type of stimulant used. Addition of neutralizing antibodies to TGF-beta increased spontaneous and cytokine-induced proliferation; this effect was dose dependent and specific because addition of an irrelevant chicken IgG had no effect on B-CLL proliferation. In resistant patients, neutralizing antibodies to TGF-beta did not increase the proliferation. The expression of TGF-beta receptors on B-CLL cells was significantly lower than the one observed on normal CD5+ B lymphocytes for which the sensitivity to TGF-beta inhibition was more marked than in CLL. In addition, we found a strong correlation between the response of leukaemic B cells to TGF-beta inhibitory action and the expression of TGF-beta receptors on these cells. In summary, TGF-beta appears to function in CLL as a negative regulator of B lymphocytes but loss of responsiveness to this factor accompanied by a decrease of TGF-beta receptor expression, might provide a selective advantage to B-CLL lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207409     DOI: 10.1046/j.1365-2141.1997.792715.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Dynamics of protein 27 of avian leukosis virus and transforming growth factor beta2 in lymphoid leukosis susceptible and resistant broiler chicken breeding stock.

Authors:  E K Barbour; M Bouljihad; B Hamdar; W Sakr; A Eid; B Safieh-Garabedian
Journal:  Vet Res Commun       Date:  1999-05       Impact factor: 2.459

Review 2.  Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.

Authors:  M C Le Bousse-Kerdilès; M C Martyré
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Role of transforming growth factor-beta in hematologic malignancies.

Authors:  Mei Dong; Gerard C Blobe
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

4.  Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma.

Authors:  M C Kyrtsonis; C Repa; G V Dedoussis; A Mouzaki; A Simeonidis; M Stamatelou; A Maniatis
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

5.  TGFbeta/BMP inhibits the bone marrow transformation capability of Hoxa9 by repressing its DNA-binding ability.

Authors:  Ning Wang; Hyung-Gyoong Kim; Claudiu V Cotta; Mei Wan; Yi Tang; Christopher A Klug; Xu Cao
Journal:  EMBO J       Date:  2006-03-09       Impact factor: 11.598

6.  Regulatory B cells and allergic diseases.

Authors:  Geunwoong Noh; Jae Ho Lee
Journal:  Allergy Asthma Immunol Res       Date:  2011-05-30       Impact factor: 5.764

7.  TGF-β/SMAD Pathway Is Modulated by miR-26b-5p: Another Piece in the Puzzle of Chronic Lymphocytic Leukemia Progression.

Authors:  Maria Elena Marquez; Sandra Sernbo; Eugenia Payque; Rita Uria; Juan Pablo Tosar; Juliana Querol; Catalina Berca; Angimar Uriepero; Daniel Prieto; Diego Alvarez-Saravia; Carolina Oliver; Victoria Irigoin; Gimena Dos Santos; Cecilia Guillermo; Ana Inés Landoni; Marcelo Navarrete; Florencia Palacios; Pablo Oppezzo
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

Review 8.  TGF-β - an excellent servant but a bad master.

Authors:  Lenka Kubiczkova; Lenka Sedlarikova; Roman Hajek; Sabina Sevcikova
Journal:  J Transl Med       Date:  2012-09-03       Impact factor: 5.531

9.  Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.

Authors:  Joanna Gora-Tybor; Jerzy Z Blonski; Tadeusz Robak
Journal:  Mediators Inflamm       Date:  2003-06       Impact factor: 4.711

10.  Identification of CD105 (endoglin) as novel risk marker in CLL.

Authors:  Sarah M Greiner; Melanie Märklin; Samuel Holzmayer; Kübra Kaban; Sophie Meyer; Clemens Hinterleitner; Claudia Tandler; Ilona Hagelstein; Gundram Jung; Helmut R Salih; Jonas S Heitmann; Joseph Kauer
Journal:  Ann Hematol       Date:  2022-01-19       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.